Outcomes in UK ACS Patients Prescribed Ticagrelor
Health Outcomes of Patients With Acute Coronary Syndromes Prescribed Ticagrelor in UK Primary Care: a Retrospective Cohort Study
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history.
The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.
調査の概要
状態
条件
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Luton、イギリス
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- First prescription (index date) for ticagrelor between Dec 2010 and Mar 2015
- At least 12 months history in database prior to first ticagrelor prescription
- Linkage to Hospital Episode Statistics (HES)
- Acute Coronary Syndrome (ACS) event in the three months prior to and including the index date
Exclusion Criteria:
Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Incidence of myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Incidence of stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Incidence of vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Time to event for composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Time to event for myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Time to event for all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Time to event for stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Time to event for vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Incidence of bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Incidence of dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Time to event for bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
Time to event for dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
時間枠:From index date up to 12 months
|
From index date up to 12 months
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
急性冠症候群の臨床試験
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research Foundation; Cornelia... と他の協力者募集ミトコンドリア病 | 網膜色素変性症 | 重症筋無力症 | 好酸球性胃腸炎 | 多系統萎縮症 | 平滑筋肉腫 | 白質ジストロフィー | 痔瘻 | 脊髄小脳失調症3型 | フリードライヒ失調症 | ケネディ病 | ライム病 | 血球貪食性リンパ組織球症 | 脊髄小脳失調症1型 | 脊髄小脳性運動失調2型 | 脊髄小脳失調症6型 | ウィリアムズ症候群 | ヒルシュスプルング病 | 糖原病 | 川崎病 | 短腸症候群 | 低ホスファターゼ症 | レーバー先天性黒内障 | 口臭 | アカラシア心臓 | 多発性内分泌腫瘍 | リー症候群 | アジソン病 | 多発性内分泌腫瘍2型 | 強皮症 | 多発性内分泌腫瘍1型 | 多発性内分泌腫瘍2A型 | 多発性内分泌腫瘍2B型 | 非定型溶血性尿毒症症候群 | 胆道閉鎖症 | 痙性運動失調 | WAGR症候群 | アニリディア | 一過性全健忘症 | 馬尾症候群 | レフサム... およびその他の条件アメリカ, オーストラリア